Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E6011 in Active Crohn's Disease
NCT02249078Phase 1Withdrawn
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of quetmolimab in Crohn's disease (5 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Number of participants with Adverse Events and Serious Adverse Events up to 3 years. Planned start Dec 2014; status: withdrawn.
02
Drugs
quetmolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT02249078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02249078.